Evidence map›Paper›PMID 40141384›Full record

ArticleInternational journal of molecular sciences2025

Differential Effects of the Prolyl-Hydroxylase Inhibitor on the Cellular Response to Radiation.

Masaki Murao, Takahiro Fukazawa, Ujjal K Bhawal, Nitesh Tewari, Nobuaki Shime, Nobuyuki Hirohashi, Keiji Tanimoto

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Masaki MuraoDepartment of Radiation Disaster Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan.
Takahiro FukazawaNatural Science Center for Basic Research and Development, Hiroshima University, Hiroshima 734-8553, Japan.
Ujjal K BhawalCenter for Global Health Research, Saveetha Institute of Medical and Technical Sciences, Saveetha Medical College and Hospitals, Saveetha University, Chennai 600077, India.ORCID 0000-0002-3746-009X
Nitesh TewariDivision of Pediatric and Preventive Dentistry, Centre for Dental Education and Research, All India Institute of Medical Sciences, New Delhi 110029, India.ORCID 0000-0002-6747-5110
Nobuaki ShimeDepartment of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
Nobuyuki HirohashiDepartment of Radiation Disaster Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan.ORCID 0000-0001-6237-214X
Keiji TanimotoDepartment of Radiation Disaster Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan.ORCID 0000-0003-4912-4197

Funding

JSPS 18K09768, 23K084770
6 · The paper itself

Abstract

The prolyl-hydroxylase inhibitor (PHI), used effectively in several countries for the treatment of renal anemia, activates the multifunctional hypoxia-inducible factors (HIFs). While hypoxic conditions in tumors are known to affect the response to radiation therapy, the effect of PHI on the radiation response of cancer cells has not been determined. Hypoxic pretreatment increased the radiation sensitivity of A549 lung adenocarcinoma cells, whereas hypoxic culture after irradiation decreased the radiation sensitivity of HSC2 oral squamous cell carcinoma cells. Treatment of PC9 lung adenocarcinoma and HSC2 cells with the PHI FG-4592 significantly increased radiation resistance, whereas A549 and TIG3 lung fibroblast cells tended to be sensitized, suggesting cell type-specific differential effects of PHI. Quantitative RT-PCR analyses revealed that the basal and radiation-inducible expressions of

Indexed as

Prolyl-Hydroxylase InhibitorsRadiation ToleranceA549 CellsBasic Helix-Loop-Helix Proteinsbcl-2-Associated X ProteinCell HypoxiaCell Line, TumorHumansProto-Oncogene Proteins c-bcl-2Tumor Suppressor Protein p53Basic Helix-Loop-Helix Proteinsbcl-2-Associated X ProteinProlyl-Hydroxylase InhibitorsProto-Oncogene Proteins c-bcl-2Tumor Suppressor Protein p53DEC2hypoxiap53prolyl-hydroxylase inhibitorradiation

Identifiers

PMID40141384
PMCPMC11943049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.